Global Age-Related Macular Degeneration Market Forecast 2026–2035: Long-Term Growth Insights
Uncover key drivers, emerging technologies, and competitive movements shaping the age-related macular degeneration market from 2026–2035 with trusted insights from The Business Research Company
How is the Age-Related Macular Degeneration Market size predicted to change over the forecast window of 2026–2035?
The age-related macular degeneration market size has experienced strong expansion in recent years. This market is expected to increase from $10.67 billion in 2025 to $11.46 billion in 2026, progressing at a compound annual growth rate (CAGR) of 7.5%. Historically, this growth can be ascribed to a globally aging population, the escalating prevalence of amd, limited treatment options available in earlier periods, growing public awareness concerning eye health, and the expansion of hospital and ophthalmology clinic infrastructure.
The age-related macular degeneration market size is anticipated to experience robust expansion over the coming years, projected to reach $15.42 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.7%. This expansion during the forecast period is attributed to the development of next-generation anti-vegf drugs, increased investment in ophthalmology research, the proliferation of specialty pharmacies and online pharmacy channels, the growing use of combination therapies, and the rising adoption of personalized treatment approaches. Significant trends for the forecast period include the increasing uptake of anti-vegf therapies, the rising utilization of nutritional supplements and low vision aids, growth in photodynamic and laser therapy procedures, the expansion of intravitreal and intravenous administration routes, and enhanced awareness alongside regular eye screening programs.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10845&type=smp
Which Drivers Are Contributing To The Expansion Of The Age-Related Macular Degeneration Market?
The escalating prevalence of age-related macular degeneration (AMD) is anticipated to boost the growth of the age-related macular degeneration (AMD) market moving forward. Age-related macular degeneration (AMD) is a progressive ocular condition impacting the macula, a small section of the retina vital for central vision. Therapies for age-related macular degeneration (AMD) assist patients with retinal disorders by mitigating the seriousness of the disease. For example, in February 2023, reports from Optimaxa, a UK-based laser eye treatment specialist, revealed that 196 million individuals worldwide were affected by age-related macular degeneration (AMD), with this figure expected to reach 288 million by 2040, making up 8.7 percent of the world’s population. Thus, the increasing prevalence of age-related macular degeneration (AMD) is propelling the age-related macular degeneration market.
What Segment Categories Are Covered In The Age-Related Macular Degeneration Market?
The age-related macular degeneration market covered in this report is segmented –
1) By Type: Wet Age-Related Macular Degeneration (AMD), Dry Age-Related Macular Degeneration (AMD)
2) By Drug: Eylea, Lucentis, Avastin, Other Drugs
3) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy
Subsegments:
1) By Wet Age-Related Macular Degeneration (AMD): Anti-VEGF Injections, Photodynamic Therapy, Laser Surgery
2) By Dry Age-Related Macular Degeneration (AMD): Nutritional Supplements, Low Vision Aids, Therapies For Geographic Atrophy
How Are Emerging Trends Affecting The Progression Of The Age-Related Macular Degeneration Market?
Leading firms within the age-related macular degeneration (AMD) sector are progressing with novel technologies, including recombinant antigen-binding fragments. Recombinant antigen-binding fragments (Fab) are genetically modified proteins, originating from antibodies, designed to specifically attach to particular antigens, frequently employed in medical treatments to suppress disease pathways. As an example, in December 2023, Enzene Biosciences, an India-based biotechnology enterprise, introduced ranibizumab, which is a recombinant monoclonal antibody fragment (Fab) specifically crafted to block vascular endothelial growth factor (VEGF), a crucial protein implicated in the formation of aberrant blood vessels in diseases like age-related macular degeneration (AMD) and diabetic macular edema (DME). Through its action of hindering VEGF, ranibizumab efficiently reduces the leakage and growth of these blood vessels, thereby aiding in vision preservation for individuals suffering from these retinal conditions. Administered via intravitreal injection, it has achieved broad adoption in clinical settings due to its effectiveness in addressing a range of retinal ailments. The market entry of ranibizumab has significantly improved therapeutic options for patients contending with these severe illnesses.
Which Major Industry Participants Are Leading The Age-Related Macular Degeneration Market Growth?
Major companies operating in the age-related macular degeneration market are F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., Outlook Therapeutics Inc., Samsung Bioepis Co. Ltd., Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.
Access The Complete Report For Deeper Market Insights:
Which Region Is Expected To Experience The Fastest Growth In The Age-Related Macular Degeneration Market?
North America was the largest region in the global age-related macular degeneration market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Age-Related Macular Degeneration Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=10845&type=smp
Browse Through More Reports Similar to the Global Age-Related Macular Degeneration Market 2026, By The Business Research Company
Non Proliferative Diabetic Retinopathy Market Report 2026
Macular Degeneration Treatment Market Report 2026
Macular Edema And Macular Degeneration Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
